NeoGenomics, Inc. $NEO Position Boosted by AlphaQuest LLC

AlphaQuest LLC grew its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 317.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 26,503 shares of the medical research company’s stock after purchasing an additional 20,158 shares during the period. AlphaQuest LLC’s holdings in NeoGenomics were worth $194,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in NEO. First Light Asset Management LLC boosted its position in shares of NeoGenomics by 90.8% during the 1st quarter. First Light Asset Management LLC now owns 6,042,822 shares of the medical research company’s stock valued at $57,346,000 after purchasing an additional 2,875,237 shares in the last quarter. Samjo Management LLC acquired a new position in shares of NeoGenomics in the first quarter worth about $5,970,000. American Century Companies Inc. boosted its holdings in shares of NeoGenomics by 14.7% in the first quarter. American Century Companies Inc. now owns 3,319,602 shares of the medical research company’s stock worth $31,503,000 after buying an additional 426,341 shares during the period. Aberdeen Group plc acquired a new position in shares of NeoGenomics in the first quarter worth about $3,920,000. Finally, Nuveen LLC acquired a new position in shares of NeoGenomics in the first quarter worth about $3,281,000. Institutional investors own 98.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Needham & Company LLC raised their target price on shares of NeoGenomics from $8.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, August 29th. Morgan Stanley set a $8.00 target price on NeoGenomics and gave the company an “equal weight” rating in a report on Wednesday, July 30th. Weiss Ratings restated a “sell (d-)” rating on shares of NeoGenomics in a report on Wednesday, October 8th. Stephens increased their target price on NeoGenomics from $6.50 to $11.00 and gave the company an “overweight” rating in a report on Tuesday, September 2nd. Finally, Cowen restated a “buy” rating on shares of NeoGenomics in a report on Friday, September 12th. Seven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, NeoGenomics presently has a consensus rating of “Hold” and an average price target of $13.11.

NeoGenomics Stock Performance

NEO stock opened at $9.77 on Monday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.58 and a current ratio of 3.91. The stock has a market cap of $1.26 billion, a P/E ratio of -11.10 and a beta of 1.61. The firm has a 50 day simple moving average of $8.76 and a 200 day simple moving average of $7.77. NeoGenomics, Inc. has a 52 week low of $4.72 and a 52 week high of $19.11.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Tuesday, October 28th. The medical research company reported $0.03 EPS for the quarter, topping the consensus estimate of $0.02 by $0.01. The business had revenue of $187.80 million during the quarter, compared to analysts’ expectations of $183.85 million. NeoGenomics had a negative net margin of 16.00% and a negative return on equity of 3.36%. The firm’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same period last year, the company posted $0.05 earnings per share. NeoGenomics has set its FY 2025 guidance at 0.080-0.120 EPS. Research analysts anticipate that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.